Patents
Spotlight on South Africa: 10 Questions for Biovac’s Patrick Tippoo
Innovation Council sat down with Patrick Tippoo, the Head of Science and Innovation at The Biovac Institute in South Africa to learn more about its activities and innovations. Established in 2003 in Cape Town, Biovac was created to distribute, manufacture, and develop vaccines and biologics for Southern Africa. Patrick, who has been with Biovac since its establishment, has more than 30 years in the industry.
The Long Wait for Innovation: The Global Patent Pendency Problem
Mark Schultz and Kevin Madigan write in their informative, and still very pertinent, 2016 paper about patent pendency issues and the reasons for, and possible solutions to, the problem. Many patent offices simply lack sufficient examiners to handle the increasing volume of patent applications, and there are deficiencies in both processes and infrastructure. One possible solution is increasing the number and qualification of examiners; many countries are already prioritizing the hiring of new examiners to tackle patent delay and backlog problems. Work sharing is another option. Patents are increasingly filed in multiple jurisdictions, and this duplication creates the opportunity to share work or expedite applications that have already been granted by recognized jurisdictions. Yet another proposed solution is the removal of obstacles to final grants. Some countries insert additional procedures and reviews in between application and grant: India, for example, has a redundant pre-grant opposition procedure, while Brazil subjects pharmaceutical patent applications to double review by both its patent office and its drug regulator. Such procedures should be re-considered in light of the substantial cost of the delays they introduce, and, where they are redundant, they should be eliminated.
Gender Profiles in UK Patenting: An analysis of female inventorship
This analysis by the UKIPO shows that, in the 1980s, women represented less than 4% of inventors on GB patent applications, but that this has steadily risen to over 8% in recent years. Although absolute numbers remain relatively low, the last 10 years have seen a 16% increase in the proportion of female inventors. The overall proportion of patents involving a female inventor (either working alone or as part of a team) has more than tripled, from 4% in 1980 to over 12% in 2015; at the same time, the last 10 years have seen the proportion of individual female inventors’ plateau at around 3.75%. The number of all-female teams has increased fivefold since 1980, but the absolute numbers are still very low, with only 0.33% of patents coming from all-female teams in 2015. Although historical analysis reveals ever-increasing levels of female patenting, the growth rate is slow and the absolute numbers are still very low. The world of patenting remains male-dominated, and, even in 2015, there is a clear gender disparity: 88% of all GB patent applications come from male individuals or all-male teams, and almost 96% teams that submit applications include at least one man.
2017 Women’s Participation in Patenting: An Analysis of PCT Applications Originating in Canada
This report from 2017, by the Canadian Intellectual Property Office, examines international patent applications filed under the Patent Cooperation Treaty (PCT), in order to determine the share of inventors who are women and the share of PCT applications with at least one woman inventor. The report studies PCT applications by Canadian applicants, and finds that Canada has seen little change in the share of inventors who are women in the last 15 years, even as the world share continues to grow.
European Inventor Award 2021 Popular Prize
The race is on to see who will win the coveted Popular Prize at the 2021 European Inventor awards. Fifteen inventors or inventor teams from around the world have been nominated for this year’s Popular Prize. They are in five categories: Industry, Lifetime achievement, Non-EPO countries, SMEs and Research.
Brazil shortens term of thousands of pharma and medical device patents
In the middle of May, the Brazilian Supreme Court issued a landmark ruling, deciding that a controversial provision of the country’s patent law guaranteeing a minimum 10-year, post-issuance term (Article 40) was unconstitutional. The court opted to apply the ruling to all current pharmaceutical and medical device patents (regardless of the specific products they relate to) that have benefited from the provisions of Article 40, as well as all patents with pending nullity actions (filed by 7th April 2021). The judgment also applies to pending applications and new filings (regardless of the length of delay they have faced).
Are Chinese politics a threat to the patent system?
In this 2-minute video, Gaétan de Rassenfosse, Chair of Innovation and IP Policy at EPFL, explains that foreign companies operating in China are less likely to have their patent applications granted than their Chinese counterparts. This discrimination occurs in technologies of strategic importance to the Chinese government, particularly in the telecommunication and biotech industries.
Opinion: How Intellectual Property Rights Helped America Fight COVID-19
James Pooley, a former deputy director general of WIPO and a member of the Center for Intellectual Property Understanding, explains in this article how past investments in R&D helped in the fight against Covid-19. Over the last 10 years alone, drug companies have invested more than $1.5 trillion in global pharmaceutical research (notably, the US—home to less than 5% of the world’s population—accounts for roughly half of all international pharmaceutical R&D spending). With this in mind, it takes years to develop a new medicine, conduct clinical studies, and navigate regulatory review; indeed, it costs $2.6 billion, on average, to bring a new drug to market. Patents, however, give innovators a fair opportunity to recoup their investment costs before generics firms can manufacture copycat medicines, making it possible for companies to chase state-of-the-art ideas.
Healthcare Innovation Main Driver of European Patent Applications in 2020
The latest statistics published by the European Patent Office (EPO) show that innovation in healthcare was the main driver of patenting activity in 2020. Medical technology was the field with the most inventions by volume, while pharmaceuticals and biotechnology were the fastest-growing areas. Indeed, in 2020, medical technology retook the top spot for most inventions (from the field of digital communication), while pharmaceuticals and biotech showed 10.2% and 6.3% increases in patent filing, respectively.